the aid library

LIST OPTIONS

Filter

13889

Financing the Pandemic Cycle: Prevention, Preparedness, Response, and Recovery and Reconstruction

Fan V. Y., Kim S., Pineda D., et al. Center for Global Development (2024) CC

The COVID-19 pandemic exposed critical gaps in the global response to health crises, particularly in the financing of pandemic prevention, preparedness, response, recovery, and reconstruction. This chapter presents a comprehensive framework for pandemic financing that spans the entire pandemic cycle... more

External Link (472)

Financing pandemic prevention, preparedness and response: lessons learned and perspectives for future

Ndembi N., Dereje N., Nonvignon J., et al. Globalization and Health (2024) CC

The attainment of global health security goals and universal health coverage will remain a mirage unless African health systems are adequately funded to improve resilience to public health emergencies. The COVID-19 pandemic exposed the global inequity in accessing medical countermeasures, leaving Af... more

External Link (381)

Estimates of aid for reproductive, maternal, newborn, and child health: findings from application of the Muskoka2 method, 2002–17

Dingle, A.; Schäferhoff, M.; Borghi, J. et al. The Lancet (2020) CC

Background Four methods have previously been used to track aid for reproductive, maternal, newborn, and child health (RMNCH). At a meeting of donors and stakeholders in May, 2018, a single, agreed method was requested to produce accurate, predictable, transparent, and up-to-date estimates that coul...d be used for analyses from both donor and recipient perspectives. Muskoka2 was developed to meet these needs. We describe Muskoka2 and present estimates of levels and trends in aid for RMNCH in 2002–17, with a focus on the latest estimates for 2017. Methods Muskoka2 is an automated algorithm that generates disaggregated estimates of aid for reproductive health, maternal and newborn health, and child health at the global, donor, and recipient-country levels. We applied Muskoka2 to the Organisation for Economic Co-operation and Development's Creditor Reporting System (CRS) aid activities database to generate estimates of RMNCH disbursements in 2002–17. The percentage of disbursements that benefit RMNCH was determined using CRS purpose codes for all donors except Gavi, the Vaccine Alliance; the UN Population Fund; and UNICEF; for which fixed percentages of aid were considered to benefit RMNCH. We analysed funding by donor for the 20 largest donors, by recipient-country income group, and by recipient for the 16 countries with the greatest RMNCH need, defined as the countries with the worst levels in 2015 on each of seven health indicators. Findings After 3 years of stagnation, reported aid for RMNCH reached $15·9 billion in 2017, the highest amount ever reported. Among donors reporting in both 2016 and 2017, aid increased by 10% ($1·4 billion) to $15·4 billion between 2016 and 2017. Child health received almost half of RMNCH disbursements in 2017 (46%, $7·4 billion), followed by reproductive health (34%, $5·4 billion), and maternal and newborn health (19%, $3·1 billion). The USA ($5·8 billion) and the UK ($1·6 billion) were the largest bilateral donors, disbursing 46% of all RMNCH funding in 2017 (including shares of their core contributions to multilaterals). The Global Fund and Gavi were the largest multilateral donors, disbursing $1·7 billion and $1·5 billion, respectively, for RMNCH from their core budgets. The proportion of aid for RMNCH received by low-income countries increased from 31% in 2002 to 52% in 2017. Nigeria received 7% ($1·1 billion) of all aid for RMNCH in 2017, followed by Ethiopia (6%, $876 million), Kenya (5%, $754 million), and Tanzania (5%, $751 million). Interpretation Muskoka2 retains the speed, transparency, and donor buy-in of the G8's previous Muskoka approach and incorporates eight innovations to improve precision. Although aid for RMNCH increased in 2017, low-income and middle-income countries still experience substantial funding gaps and threats to future funding. Maternal and newborn health receives considerably less funding than reproductive health or child health, which is a persistent issue requiring urgent attention. Funding Bill & Melinda Gates Foundation; Partnership for Maternal, Newborn & Child Health. more

External Link (384)

National spending on health by source for 184 countries between 2013 and 2040

Dieleman, J.; Templin, T.; Sadat, N. et al. (2016) CC

A general consensus exists that as a country develops economically, health spending per capita rises and the share of that spending that is prepaid through government or private mechanisms also rises. However, the speed and magnitude of these changes vary substantially across countries, even at simi...lar levels of development. In this study, we use past trends and relationships to estimate future health spending, disaggregated by the source of those funds, to identify the financing trajectories that are likely to occur if current policies and trajectories evolve as expected. Methods We extracted data from WHO's Health Spending Observatory and the Institute for Health Metrics and Evaluation's Financing Global Health 2015 report. We converted these data to a common purchasing power-adjusted and inflation-adjusted currency. We used a series of ensemble models and observed empirical norms to estimate future government out-of-pocket private prepaid health spending and development assistance for health. We aggregated each country's estimates to generate total health spending from 2013 to 2040 for 184 countries. We compared these estimates with each other and internationally recognised benchmarks. Findings Global spending on health is expected to increase from US$7·83 trillion in 2013 to $18·28 (uncertainty interval 14·42–22·24) trillion in 2040 (in 2010 purchasing power parity-adjusted dollars). We expect per-capita health spending to increase annually by 2·7% (1·9–3·4) in high-income countries, 3·4% (2·4–4·2) in upper-middle-income countries, 3·0% (2·3–3·6) in lower-middle-income countries, and 2·4% (1·6–3·1) in low-income countries. Given the gaps in current health spending, these rates provide no evidence of increasing parity in health spending. In 1995 and 2015, low-income countries spent $0·03 for every dollar spent in high-income countries, even after adjusting for purchasing power, and the same is projected for 2040. Most importantly, health spending in many low-income countries is expected to remain low. Estimates suggest that, by 2040, only one (3%) of 34 low-income countries and 36 (37%) of 98 middle-income countries will reach the Chatham House goal of 5% of gross domestic product consisting of government health spending. Interpretation Despite remarkable health gains, past health financing trends and relationships suggest that many low-income and lower-middle-income countries will not meet internationally set health spending targets and that spending gaps between low-income and high-income countries are unlikely to narrow unless substantive policy interventions occur. Although gains in health system efficiency can be used to make progress, current trends suggest that meaningful increases in health system resources will require concerted action. Funding Bill & Melinda Gates Foundation. more

Tracking AMR Country Self Assessment Survey (TrACSS) 2022 Country Report Namibia

Food and Agriculture Organization of the United Nations FAO; UN environment programme; World Health Organization WHO; et al. (2022) C_WHO

Fact sheet

External Link (351)

Malaria “chemoprevention and vaccination strategies” for children living in endemic areas of Africa: a review

Nambatya, W.; M. Ocan, B. Robberstad , et al. (2025) CC

Front. Malar. 3:1336324. doi: 10.3389/fmala.2025.1336324

External Link (230)

Antimalarial drugs for treating and preventing malaria in pregnant and lactating women

Saito, M.; Gilder, M. E.; McGready, R. et al. (2018) C2

EXPERT OPINION ON DRUG SAFETY 2018, VOL. 17, NO. 11, 1129–1144. Malaria during and after pregnancy contributes significantly to maternal mortality and adverse fetal outcomes. While effective and safe antimalarial treatments are essential, quinine — an older, less effective drug — has long bee... more

External Link (137)

Empfehlungen zur Malariaprophylaxe

Rothe, C.; O. Veit, D. Rosenbusch, et al. Georg Thieme Verlag KG (2024) CC2

Flugmedizin · Tropenmedizin · Reisemedizin - FTR 2024; 31(04): 165-206 DOI: 10.1055/a-2351-8414

External Link (210)

Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses

Cohee, LM.; C. Opondo, S. E Clarke, et al. (2020) C1

Lancet Glob Health 2020 Published Online October 22, 2020 https://doi.org/10.1016/S2214-109X(20)30325-9

External Link (216)

Identification and management of co-infections in people with malaria

Cunnington, A.; A. Abbara, F. Kaduni Bawa, et al. (2024) CC2

BMJ 2024 Mar 13:384:e077512. doi: 10.1136/bmj-2023-077512. Co-infections in individuals with malaria are common, particularly in endemic areas, and can significantly impact disease severity and outcomes. Effective management requires prompt diagnosis of both malaria and any co-occurring infections,... more

External Link (217)

HIV-1 Impact on Malaria Transmission: A Complex and Relevant Global Health Concern

Roberds, A.; E. Ferraro, S. Luckhart, et al. (2021) CC2

Front. Cell. Infect. Microbiol., 12 April 2021 Sec. Parasite and Host Volume 11 - 2021 | https://doi.org/10.3389/fcimb.2021.656938 Over the past several decades, malaria/HIV-1 co-infection has become a significant global public health problem in co-endemic areas of the world.

External Link (225)

The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region

Unger, H.W.; S. Acharya, L. Arnold, et al (2023) C1

Lancet Glob Health 2023; 11: e1805–18

External Link (185)

Audience Segmentation for Malaria

Moore, J.; A. Orji, G. Hunter, et al. John Hopkins Center for Communication Programs (2025) CC

This course is intended for use by social and behavior change (SBC) and service delivery professionals to encourage appropriate use of malaria tests and treatment by employing segmentation based on attitudes and behaviors of their intended audience(s).

External Link (296)

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double- blind, randomised, phase 3 trial

Datoo, M.S.; A. Dicko, H.Tinto, et al. (2024) CC

Lancet 2024; 403: 533–44 R21/Matrix-M was well tolerated and offered high efficacy against clinical malaria in African children. This low-cost, high-efficacy vaccine is already licensed by several African countries, and recently received a WHO policy recommendation and prequalification, offerin... more

External Link (240)

Global, regional, and national burden of malaria, 1990–2021: Findings from the global burden of disease study 2021

Zhang, S.-X.; G.B. Yung, J. Yung, et al. (2024) CC

Decoding Infection and Transmission Volume 2, 2024, 100030

External Link (396)

Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000–22: a spatial and temporal modelling study

Weiss, D.J.; P.A. Dzianach, A. Saddler, et al. (2025) C1

The Lancet Volume 405, Issue 10483p979-990March 22, 2025

External Link (596)

TACT trainer and trainee manuals and patient leaflet

ACT Consortium; Ministry of Health and Social Welfare (Tanzania); Clinical Officers in Hai Distrrict et al. (2025) CC

The TACT training manuals and patient leaflet were developed as part of the ACT Consortium's initiative to improve malaria case management by promoting the correct use of rapid diagnostic tests (RDTs). The TACT ("Targeting ACTs") initiative aims to ensure that artemisinin-based combination therapies... more

External Link (218)

Manuais TACT para formadores e formandos e folheto TACT para pacientes

ACT Consortium; Ministry of Health and Social Welfare (Tanzania); Clinical Officers in Hai Distrrict et al. (2025) CC

Os manuais de formação TACT e o folheto para o paciente foram desenvolvidos no âmbito da iniciativa do ACT Consortium para melhorar a gestão dos casos de malária e promover a utilização correta dos testes de diagnóstico rápido (RDT). A iniciativa TACT ("Targeting ACTs") visa garantir a util... more

External Link (192)

Using the role model approach to optimise caregiver administration of sulfadoxine-pyrimethamine amodiaquine to children aged 3–59 months in Burkina Faso, Chad and Togo: findings from an evaluation

Donovan, L.; M. Shafique, A. Wharton-Smith, et al. (2024) CC2

Malaria Journal (2024) 23:255. Seasonal malaria chemoprevention (SMC) is a World Health Organization-recommended intervention for the prevention of malaria among children at high risk in areas with seasonal transmission. During the coronavirus disease 2019 (COVID-19) pandemic, SMC drug distribution ... more

External Link (242)

Malaria amongst children under five in sub-Saharan Africa: a scoping review of prevalence, risk factors and preventive interventions

Sarfo, J.O.; M. Amoadu, P.Y. Kordorwu, et al. (2023) CC2

Eur J Med Res 28, 80 (2023). https://doi.org/10.1186/s40001-023-01046-1. Africa has a higher burden of malaria-related cases and deaths globally. Children under five accounted for over two-thirds of all malaria deaths in sub-Saharan Africa (SSA). This scoping review aims to map evidence of the preva... more